Trial reportInfectious diseases in obstetrics and gynecology2012
Vaginal impact of the oral administration of total freeze-dried culture of LCR 35 in healthy women.
Trial report in Infectious diseases in obstetrics and gynecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- ProbioticFrontiers in cellular and infection microbiology · 2021Trial
- Recovery ofNutrients · 2020Trial
- Comparative phase I randomized open-label pilot clinical trial of GynophilusEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Trial
- A Healthy Vaginal Microbiota Remains Stable during Oral Probiotic Supplementation: A Randomised Controlled Trial.Microorganisms · 2023Article
- Role of the vaginal microbiome in miscarriage: exploring the relationship.Frontiers in cellular and infection microbiology · 2023Review
- Lacticaseibacillus rhamnosus Lcr35 Stimulates Epithelial Vaginal Defenses upon Gardnerella vaginalis Infection.Infection and immunity · 2022Article
- Cervicovaginal microbiota isolated from healthy women exhibit probiotic properties and antimicrobial activity against pathogens isolated from cervical cancer patients.Archives of microbiology · 2022Article
- The Use of Probiotics for Management and Improvement of Reproductive Eubiosis and Function.Nutrients · 2022Review
- Effects of a 10-Strain Oral Probiotic on Parameters of Vaginal Health and Microbial Community: A Pilot Clinical Study.International journal of women's health · 2022Article
- Vaginal Probiotics for Reproductive Health and Related Dysbiosis: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
- Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35.Scientific reports · 2020Article
- Probiotics Dietary Supplementation for Modulating Endocrine and Fertility Microbiota Dysbiosis.Nutrients · 2020Review
- Selection of New Probiotics for Endometrial Health.Frontiers in cellular and infection microbiology · 2019Article
- Functional genomics of lactic acid bacteria: from food to health.Microbial cell factories · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of probiotics in the prevention or treatment of some vaginal infections has been the subject of numerous studies. To assess the presence of Lactobacillus casei rhamnosus (LCR35) in the vagina after an oral administration, an open randomised pilot study was conducted on 20 healthy women of child-bearing age. Materials and Methods. 2 groups of 10 women were given a 28-day oral course, that is, at least 108 CFU/day (group 1) or 2 × 108 CFU/day (group 2) of LCR35. Nugent score and vaginal screening for LCR35 were undertaken before and after 28 days of treatment. Results. The mean Nugent score decreased in group 1 (-0,2) as well as in group 2 (-0,3). 10% of women in group 1 versus 40% of women in group 2 were carrying LCR35 at the end of the trial. Conclusion. LCR35, at the minimal dose of 2 × 108 CFU/day, can return the Nugent score to normal in healthy women of child-bearing age, by means of a well-tolerated vaginal temporary presence. Phase III clinical trials will specify the preventive or curative impact of this orally administered strain on a range of vaginal disorders such as bacterial vaginosis or vulvovaginal candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.